Advertisement

Topics

Eli Lilly To Present Post-hoc Analyses On Emgality Compared To Placebo

07:33 EDT 12 Jul 2019 | RTTNews

Eli Lilly and Co. (LLY) announced Friday the presentation of post-hoc analyses showing improvements in daily functioning and reductions in disability in patients with chronic and episodic migraine treated with Emgality (galcanezumab-gnlm) compared to placebo.

Original Article: Eli Lilly To Present Post-hoc Analyses On Emgality Compared To Placebo

NEXT ARTICLE

More From BioPortfolio on "Eli Lilly To Present Post-hoc Analyses On Emgality Compared To Placebo"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...